lyophilization is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
=== Toxicology === Mitragynine toxicity in humans is largely unknown, as animal studies show significant species-specific differences in mitragynine tolerance. Mitragynine toxicity in humans is rarely reported although specific examples of seizures and liver toxicity in kratom consumers have been reported. Due to cytochrome P450 enzyme inhibition, the combination of mitragynine with other drugs poses concern for adverse reactions to mitragynine. Fatalities involving mitragynine tend to include its use in combination with opioids and some cough suppressants. Post-mortem toxicology screens indicate a wide range of mitragynine blood concentrations ranging from 10 μg/L to 4800 μg/L, making it difficult to calculate what constitutes a toxic dose in humans. These variations are suggested to result from differences in the toxicology assays used, and how long after death the assays were conducted.
=== Comparison to other formulations === Lisdexamphetamine dimesylate is one marketed formulation delivering dextroamphetamine. The following table compares the drug to other amphetamine pharmaceuticals.
where z is the number of positive or negative charges of the ion, e is the elementary charge and m is the mass of the ion. An electric excitation signal having a frequency f will therefore resonate with ions having a mass-to-charge ratio m/z given by
Sources: en.wikipedia.org
The patient is immunocompromised (for example, in AIDS or after chemotherapy); The infectious agent is of an uncommon nature (e.g. tropical diseases); The disease has not responded to first line antibiotics; The disease might be dangerous to other patients, and the patient might have to be isolated
=== The American Revolution === After his disenchantment with socialism, Hitchens increasingly emphasized the centrality of the American Revolution and the U.S. Constitution to his political philosophy. As early as 2002, Hitchens wrote, "as the third millennium gets under way, and as the Russian and Chinese and Cuban revolutions drop below the horizon, it is possible to argue that the American revolution, with its promise of cosmopolitan democracy, is the only 'model' revolution that humanity has left to it". His enthusiasm for the U.S. Bill of Rights contrasts with a dim opinion of constitutional politics on the other side of the Atlantic. Hitchens notes, "the utter failure [of the EU] to compose a viable constitution" and the "brevity of the British constitution, perhaps because the motherland of the English-speaking peoples has absent-mindedly failed to evolve one in written form".
AABB publishes a variety of other materials for the blood and biotherapies field, including the standards by which it accredits institutions. Since 1953, the organization has also operated a National Blood Exchange to facilitate transfers of blood products during shortages or when rare blood types are required. On June 1, 2018, Debra BenAvram, FASAE, CAE, became the association's chief executive officer (CEO).
== Contraindications and special caution == Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.
Sources: en.wikipedia.org
=== Secondary Sources === Blackmore, Tim (2010), "Save Now [Y/N]? Machine Memory at War in Iain M. Banks' Look to Windward", Bulletin of Science, Technology & Society, 30 (4): 259–273, doi:10.1177/0270467610373816, ISSN 0270-4676, S2CID 144415805 Brown, Chris (2001), "'Special Circumstances': Intervention by a Liberal Utopia", Millennium – Journal of International Studies, 30 (3): 625–626, doi:10.1177/03058298010300031601, S2CID 143328512. Horwich, David (21 January 2002), "Culture Clash: Ambivalent Heroes and the Ambiguous Utopia in the Work of Iain M. Banks", Strange Horizons, retrieved 3 August 2021. Jackson, Patrick Thaddeus; Heilman, James (2008), "Outside Context Problems: Liberalism and the Other in the Work of Iain M.Banks", in Hassler, D.M.; Wilcox, C. (eds.), New Boundaries in Political Science Fiction, University of South Carolina Press, pp. 235–258, ISBN 978-1-57003-736-8, retrieved 9 December 2008. Lippens, Ronnie (2002), "Imachinations of Peace: Scientifictions of Peace in Iain M. Banks's The Player of Games", Utopian Studies, 13 (1): 135–147, ISSN 1045-991X, OCLC 5542757341. Newitz, Annalee (2019), The future of another timeline, Little, Brown Book Group Limited, ISBN 978-0-356-51123-8, OCLC 1059268855. Norman, Joseph S. (2021), The Culture of "The Culture": Utopian Processes in Iain M. Banks's Space Opera Series, Oxford University Press, ISBN 978-1-78962-174-7, OCLC 1120943463. Rumpala, Yannick (2012), "Artificial intelligences and political organization: An exploration based on the science fiction work of Iain M.
== Urine tests == Urine bilirubin may also be clinically significant. Bilirubin is not normally detectable in the urine of healthy people. If the blood level of conjugated bilirubin becomes elevated, e.g. due to liver disease, excess conjugated bilirubin is excreted in the urine, indicating a pathological process. Unconjugated bilirubin is not water-soluble and so is not excreted in the urine. Testing urine for both bilirubin and urobilinogen can help differentiate obstructive liver disease from other causes of jaundice. As with billirubin, under normal circumstances, only a very small amount of urobilinogen is excreted in the urine. If the liver's function is impaired or when biliary drainage is blocked, some of the conjugated bilirubin leaks out of the hepatocytes and appears in the urine, turning it dark amber. However, in disorders involving hemolytic anemia, an increased number of red blood cells are broken down, causing an increase in the amount of unconjugated bilirubin in the blood. Because the unconjugated bilirubin is not water-soluble, one will not see an increase in bilirubin in the urine. Because there is no problem with the liver or bile systems, this excess unconjugated bilirubin will go through all of the normal processing mechanisms that occur (e.g., conjugation, excretion in bile, metabolism to urobilinogen, reabsorption) and will show up as an increase of urobilinogen in the urine. This difference between increased urine bilirubin and increased urine urobilinogen helps to distinguish between various disorders in those systems.
Most of the structures that make up animals, plants and microbes are made from four basic classes of molecules: amino acids, carbohydrates, nucleic acid and lipids (often called fats). As these molecules are vital for life, metabolic reactions either focus on making these molecules during the construction of cells and tissues, or on breaking them down and using them to obtain energy, by their digestion. These biochemicals can be joined to make polymers such as DNA and proteins, essential macromolecules of life.
== Toxicity == Overdose is commonly broken into two categories – liver toxicity (from paracetamol poisoning) and dextropropoxyphene overdose. It may also account for mood- or thought-altering effects. An overdose of dextropropoxyphene may lead to various systemic effects. Excessive opioid receptor stimulation is responsible for the CNS depression, respiratory depression, aspiration pneumonia, miosis, and gastrointestinal effects seen in propoxyphene poisoning. In the presence of amphetamine, propoxyphene overdose increases CNS stimulation and may cause fatal convulsive seizures. In addition, both propoxyphene and its metabolite norpropoxyphene have local anesthetic effects at concentrations about 10 times those necessary for opioid effects. Norpropoxyphene is a more potent local anesthetic than propoxyphene, and they are both more potent than lidocaine. Local anesthetic activity appears to be responsible for the arrhythmias and cardiovascular depression seen in propoxyphene poisoning. Both propoxyphene and norpropoxyphene are potent blockers of cardiac membrane sodium channels, and are more potent than lidocaine, quinidine, and procainamide in this respect. As a result, propoxyphene and norpropoxyphene appear to have the characteristics of a Vaughn-Williams Class Ic antiarrhythmic. These direct cardiac effects include decreased heart rate (i.e. cardiovascular depression), decreased contractility, and decreased electrical conductivity (i.e., increased PR, AH, HV, and QRS intervals).
== Adverse effects == Common side effects include pneumonia and urinary tract infections. Severe side effects may include blood clots or cardiac arrest. Andexanet alfa has a boxed warning that it is associated with arterial and venous blood clots, ischemic events, cardiac arrest, and sudden deaths.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.